Clinical Trials
28 trialsA Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma
Shandong Cancer Hospital and Institute
Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC
Guangdong Association of Clinical Trials
The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC
Chongqing University Cancer Hospital
Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Efficacy of Argon-Helium Cryoablation Plus PD-1 Inhibitors in NSCLC
The First Hospital of Hebei Medical University
Neoadjuvant Therapy for Locally Advanced Colon Cancer
Zhejiang University
Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer
Fujian Medical University
Conversion Effects of PD-1 Antibody Camrelizumab Combined With Nab-POF Regimen Chemotherpy in Patients With Initially Unresectable Locally Advanced or Limited Metastatic Gastric or Gastroesophageal Junction Adenocarcinomaļ¼FDZL-GC001 Trial
Fudan University
CCGLC-005
Tongji Hospital
NEOPBOSCC
Hospital of Stomatology, Wuhan University
Neoadjuvant Immunotherapy for Resectable Gastric Cancer
Qilu Hospital of Shandong University
Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma
Nanfang Hospital, Southern Medical University
Neoadjuvant Treatment Based on Gastric Cancer Molecular Subtyping.
Fujian Medical University
Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma
Sun Yat-sen University
The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer
The First Hospital of Jilin University
Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.
Beijing Friendship Hospital
Microwave Ablation Combined With Camrelizumab in the Treatment of Early Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma
Shanghai Jiao Tong University School of Medicine
Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors
Beijing Friendship Hospital
SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer
Sun Yat-sen University
PD-1 Antibody in EBV Positive Metastatic Gastric Cancer Patients.
Sun Yat-sen University
GTN
Peking Union Medical College Hospital
ACABC
Peking Union Medical College Hospital
Efficacy of Neoadjuvant PD-1 Blockade Plus Chemotherapy for Esophageal Squamous Cell Carcinoma
Guangzhou Institute of Respiratory Disease
A Trial of SHR-1210 (an Anti-PD-1 Antibody) in Combination With Apatinib in Patients With Advanced TNBC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal Cancer
Hangzhou Cancer Hospital
APFAO
Peking University People's Hospital
Combination of Radiotherapy and SHR-1210 to Treat Patients With ESCC
Tianjin Medical University Cancer Institute and Hospital